[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344307-105":59,"doc-detail-344307-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","variability-in-morphology-and-immunohistochemistry-of-crohns-disease-associated-small-bowel-neoplasms-implications-of-claudin-18-and-cadherin-17-expression-for-tumor-targeted-immunotherapies","Variability in morphology and immunohistochemistry of Crohn’s disease-associated small bowel neoplasms - implications of Claudin 18 and Cadherin 17 expression for tumor-targeted immunotherapies","","Crohn’s disease-associated small bowel neoplasms (CD-SBNs) are investigated for morphological and immunohistochemical variability, focusing on Claudin 18 and Cadherin 17. The study compares expression patterns with related biomarkers and explores links between Claudin 18 expression and gastric phenotype. Histology and immunohistochemistry are performed on 25 CD-SBNs, evaluating tubular versus dysplasia morphology. Results show frequent Cadherin 17 retention, common co-expression, and mucin associations supporting CD-SBN candidacy for targeted immunotherapies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/variability-in-morphology-and-immunohistochemistry-of-crohns-disease-associated-small-bowel-neoplasms-implications-of-claudin-18-and-cadherin-17-expression-for-tumor-targeted-immunotherapies/344307/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/variability-in-morphology-and-immunohistochemistry-of-crohns-disease-associated-small-bowel-neoplasms-implications-of-claudin-18-and-cadherin-17-expression-for-tumor-targeted-immunotherapies/344307.png","ImageObject",300,407,{"name":92,"@type":93},"Theodora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What biomarkers are examined in Crohn’s disease-associated small bowel neoplasms?","Question",{"text":112,"@type":113},"The study examines Cadherin 17 and Claudin 18 expression in Crohn’s disease-associated small bowel neoplasms, evaluating their distribution and potential associations with phenotype.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many CD-SBN cases were analyzed, and what methods were used?",{"text":117,"@type":113},"Histological and immunohistochemical examinations were performed on 25 CD-SBNs. Expression levels of Cadherin 17 and Claudin 18 were identified and compared across cases.",{"name":119,"@type":110,"acceptedAnswer":120},"What key findings support targeted immunotherapy relevance?",{"text":121,"@type":113},"Cadherin 17 expression was frequently retained, and Claudin 18 was often co-expressed. Claudin 18 correlated with gastric mucin expression, suggesting candidates for Claudin 18- and Cadherin 17-targeted immunotherapies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344307,1790120760,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","Virchows Archiv (2025) 486:595–603  \n[https://doi.org/10.1007/s00428-024-03896-4](https://doi.org/10.1007/s00428-024-03896-4)  \nVariability in morphology and immunohistochemistry of Crohn’s disease‑associated small bowel neoplasms: implications of Claudin 18 and Cadherin 17 expression for tumor‑targeted immunotherapies  \nMai Iwaya1 · Makoto Kodama2 · Keiko Abe2 · Kahoko Maeda1 · Tomoyuki Nakajima1 · Takeshi Uehara3 · Risa Nishio4 · Tetsuo Yamana4 · Robert Riddell5,6 · Hiroyoshi Ota7  \nReceived: 24 May 2024 / Revised: 22 July 2024 / Accepted: 11 August 2024 / Published online: 21 August 2024 © The Author(s) 2024  \nAbstract  \nAims: Inflammatory bowel disease-associated colorectal carcinomas are known to have different morphology, immunoprofile, and genetic findings from sporadic colorectal carcinomas; however, little is known for Crohn’s disease-associated small bowel neoplasms (CD-SBNs) . Cadherin 17 is a useful biomarker of adenocarcinomas with intestinal phenotype and recently reported as an ideal target for chimeric antigen receptor T-cells (CAR-T) therapy for gastrointestinal carcinoma. Claudin 18 is a cell adhesion protein, and Claudin18 isoform 2 (CLDN18.2) is frequently expressed at high levels in gastric-type adenocarcinoma. Zolbetuximab, a targeted monoclonal antibody, has been developed for CLDN18.2-positive gastroesophageal adenocarcinoma. We examined a series of CD-SBNs for both Cadherin 17 and Claudin 18, and also hypothesized that expression of Claudin 18 was associated with gastric phenotype.  \nMethods and results: We performed histological and immunohistochemical examinations on 25 CD-SBNs. Most of adenocarcinomas showed tubular morphology as seen in gastric carcinomas, whereas a subset of dysplasia was morphologically similar to that of the large bowel. Cadherin17 and Claudin 18 expression was identified in 93% and 57% CD-associatedadenocarcinomas respectively. In Cadherin 17-positive CD-SBNs, frequent MUC5AC, MUC6, and Claudin18 expression was identified (61%, 57%, and 57%, respectively) . Claudin 18-positive CD-SBNs showed significantly more MUC5AC and MUC6 expression than Claudin 18-negative CD-SBNs (P = 0.005, \u003C 0.001 respectively) .  \nConclusion: In CD-associated small bowel adenocarcinomas, Cadherin 17 expression was frequently retained and Claudin 18 was frequently co-expressed. Claudin 18 had a positive correlation with the expression of gastric mucins. These results suggest that CD-associated small bowel adenocarcinomas may be candidates for Cadherin 17-and Claudin 18-targeted immunotherapies.  \nKeywords Crohn’s disease, small bowel · Inflammatory bowel disease-associated carcinoma, dysplasia · Claudin 18 and Cadherin 17  \n* Mai Iwaya[mkatou@shinshu-u.ac.jp](mkatou@shinshu-u.ac.jp)  \n1 Department of Laboratory Medicine, Shinshu University Hospital, 3-1-1 Asahi, Matsumoto, Nagano, Japan  \n2 Department of Pathology, Tokyo Yamate Medical Center, Tokyo, Japan  \n3 Department of Laboratory Medicine, Shinshu University School of Medicine, Matsumoto, Japan  \n4 Department of Coloproctology Center, Tokyo Yamate Medical Center, Tokyo, Japan  \n5 Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada  \n6 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada  \n7 Department of Clinical Laboratory Sciences, School of Health Sciences, Shinshu University, Matsumoto, Japan  \nIntroduction  \nCrohn’s disease (CD) and ulcerative colitis (UC) are the two most common forms of inflammatory bowel disease (IBD) . Patients with IBD have an increased lifetime risk of developing colorectal adenocarcinoma (CRC) . The molecular pathogenesis of colitis-associated carcinoma (CAC) is different than that of sporadic CRC, suggested that genomic changes linked to the effects of continuous inflammation and repeated mucosal injury in the setting of IBD [1 , 2] . Although recent studies have shown that the risk of IBD patients developing CRC has decreased, probably as a resul","cbCaivVQSUjMCqZj","https://ap.wps.com/l/cbCaivVQSUjMCqZj","pdf",2998713,"English","# Abstract\n## Aims\n## Methods and results\n## Conclusion\n# Introduction\n# Cadherin-17 (CDH17)\n# Claudins and Claudin 18 (CLDN18)","[{\"question\":\"What biomarkers are examined in Crohn’s disease-associated small bowel neoplasms?\",\"answer\":\"The study examines Cadherin 17 and Claudin 18 expression in Crohn’s disease-associated small bowel neoplasms, evaluating their distribution and potential associations with phenotype.\"},{\"question\":\"How many CD-SBN cases were analyzed, and what methods were used?\",\"answer\":\"Histological and immunohistochemical examinations were performed on 25 CD-SBNs. Expression levels of Cadherin 17 and Claudin 18 were identified and compared across cases.\"},{\"question\":\"What key findings support targeted immunotherapy relevance?\",\"answer\":\"Cadherin 17 expression was frequently retained, and Claudin 18 was often co-expressed. Claudin 18 correlated with gastric mucin expression, suggesting candidates for Claudin 18- and Cadherin 17-targeted immunotherapies.\"}]","Variability in morphology and immunohistochemistry of Crohn’s disease-associated small bowel neoplasms - implications of Claudin 18 and Cadherin 17 expression for tumor-targeted immunotherapies | PDF",1790053375,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/690902d37b8eddd9e849d842a13c9bc9.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11e0e71f547027ae1ec92084a3ab5c2e.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4970b38ab50dc560a53688cbd8eb118.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/794e83f876fc7f7d8962e21b119e9a5e.webp",980,1301]